Medications for obesity and diabetes await ARS coverage

In the Dominican Republic, innovative medications for the treatment of obesity and diabetes remain inaccessible to patients through health insurance providers (ARS). Although these drugs were officially added to the national Basic Medication List over a year ago, the inclusion has not yet resulted in effective coverage for the public.

The delay in implementation leaves patients without the intended financial support for these treatments. The situation highlights a gap between the formal regulatory approval of these medications and their practical availability within the national healthcare insurance system.